查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1530970

灭活疫苗市场 - 2024-2034 年全球产业分析、规模、份额、成长、趋势与预测

Inactivated Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 167 Pages | 商品交期: 2-10个工作天内

价格

灭活疫苗市场 - 报告范围

TMR 关于全球灭活疫苗市场的报告研究了过去以及当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。年期间，考虑2024年为基准年，2034年为预测年。报告也提供了2024年至2034年全球灭活疫苗市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解灭活疫苗市场。

市场概况
2023年市场价值 406 亿美元
2034 年市场价值 748 亿美元
复合年增长率 5.7%

该报告深入探讨了全球灭活疫苗市场的竞争格局。全球灭活疫苗市场的主要参与者已经确定，并对每个参与者的不同属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球灭活疫苗市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：依疫苗类型

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依疫苗类型，2020-2034
    • 病毒疫苗
    • 细菌疫苗
  • 市场吸引力：按疫苗类型

第 7 章：全球市场分析与预测：按灭活方法

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按失活方法，2020-2034年
    • 溶剂洗涤法
    • 辐射法
    • pH值浓度
    • 其他（热灭活等）
  • 市场吸引力：按失活方法

第 8 章：全球市场分析与预测：按管理途径

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依给药途径，2020-2034年
    • 口服
    • 皮下
    • 静脉
  • 市场吸引力：依给药途径分类

第 9 章：全球市场分析与预测：按最终用户

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2020-2034
    • 医院
    • 专科诊所
    • 家庭护理设置
    • 其他（研究中心等）
  • 市场吸引力：按最终用户划分

第 10 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力：按地区

第 11 章：北美市场分析与预测

第 12 章：欧洲市场分析与预测

第 13 章：亚太市场分析与预测

第 14 章：拉丁美洲市场分析与预测

第 15 章：中东和非洲市场分析与预测

第16章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • GSK plc
    • Novartis AG
    • Mylan NV
    • Sanofi SA
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • Bristol-Myers Squibb Company
    • Bharat Biotech
    • Serum Institute of India
    • INOVIO Pharmaceuticals, Inc.
Product Code: TMRGL31316

Inactivated Vaccines Market - Scope of Report

TMR's report on the global inactivated vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global inactivated vaccines market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global inactivated vaccines market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the inactivated vaccines market.

Market Snapshot
Market Value in 2023US$ 40.6 Bn
Market Value in 2034US$ 74.8 Bn
CAGR5.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global inactivated vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global inactivated vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global inactivated vaccines market.

The report delves into the competitive landscape of the global inactivated vaccines market. Key players operating in the global inactivated vaccines market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global inactivated vaccines market profiled in this report.

Key Questions Answered in Global inactivated vaccines Market Report:

  • What is the sales/revenue generated by inactivated vaccines across all regions during the forecast period?
  • What are the opportunities in the global inactivated vaccines market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Inactivated Vaccines Market - Research Objectives and Research Approach

The comprehensive report on the global inactivated vaccines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global inactivated vaccines market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global inactivated vaccines market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Inactivated Vaccines Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Inactivated Vaccines Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Inactivated Vaccines Market Analysis and Forecast, by Vaccine Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Vaccine Type, 2020-2034
    • 6.3.1. Viral Vaccine
    • 6.3.2. Bacterial Vaccine
  • 6.4. Market Attractiveness, by Vaccine Type

7. Global Inactivated Vaccines Market Analysis and Forecast, by Method of Inactivation

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 7.3.1. Solvent Detergent Method
    • 7.3.2. Radiation Method
    • 7.3.3. pH Concentration
    • 7.3.4. Others (Heat Inactivation, etc.)
  • 7.4. Market Attractiveness, by Method of Inactivation

8. Global Inactivated Vaccines Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 8.3.1. Oral
    • 8.3.2. Subcutaneous
    • 8.3.3. Intravenous
  • 8.4. Market Attractiveness, by Route of Administration

9. Global Inactivated Vaccines Market Analysis and Forecast, by End-user

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2020-2034
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Homecare Settings
    • 9.3.4. Others (Research Centers, etc.)
  • 9.4. Market Attractiveness, by End-user

10. Global Inactivated Vaccines Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Inactivated Vaccines Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 11.2.1. Viral Vaccine
    • 11.2.2. Bacterial Vaccine
  • 11.3. Market Attractiveness, by Vaccine Type
  • 11.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 11.4.1. Solvent Detergent Method
    • 11.4.2. Radiation Method
    • 11.4.3. pH Concentration
    • 11.4.4. Others (Heat Inactivation, etc.)
  • 11.5. Market Attractiveness, by Method of Inactivation
  • 11.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 11.6.1. Oral
    • 11.6.2. Subcutaneous
    • 11.6.3. Intravenous
  • 11.7. Market Attractiveness, by Route of Administration
  • 11.8. Market Value Forecast, by End-user, 2020-2034
    • 11.8.1. Hospitals
    • 11.8.2. Specialty Clinics
    • 11.8.3. Homecare Settings
    • 11.8.4. Others (Research Centers, etc.)
  • 11.9. Market Attractiveness, by End-user
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Vaccine Type
    • 11.11.2. By Method of Inactivation
    • 11.11.3. By Route of Administration
    • 11.11.4. By End-user
    • 11.11.5. By Country

12. Europe Inactivated Vaccines Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 12.2.1. Viral Vaccine
    • 12.2.2. Bacterial Vaccine
  • 12.3. Market Attractiveness, by Vaccine Type
  • 12.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 12.4.1. Solvent Detergent Method
    • 12.4.2. Radiation Method
    • 12.4.3. pH Concentration
    • 12.4.4. Others (Heat Inactivation, etc.)
  • 12.5. Market Attractiveness, by Method of Inactivation
  • 12.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.6.1. Oral
    • 12.6.2. Subcutaneous
    • 12.6.3. Intravenous
  • 12.7. Market Attractiveness, by Route of Administration
  • 12.8. Market Value Forecast, by End-user, 2020-2034
    • 12.8.1. Hospitals
    • 12.8.2. Specialty Clinics
    • 12.8.3. Homecare Settings
    • 12.8.4. Others (Research Centers, etc.)
  • 12.9. Market Attractiveness, by End-user
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Vaccine Type
    • 12.11.2. By Method of Inactivation
    • 12.11.3. By Route of Administration
    • 12.11.4. By End-user
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Inactivated Vaccines Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 13.2.1. Viral Vaccine
    • 13.2.2. Bacterial Vaccine
  • 13.3. Market Attractiveness, by Vaccine Type
  • 13.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 13.4.1. Solvent Detergent Method
    • 13.4.2. Radiation Method
    • 13.4.3. pH Concentration
    • 13.4.4. Others (Heat Inactivation, etc.)
  • 13.5. Market Attractiveness, by Method of Inactivation
  • 13.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.6.1. Oral
    • 13.6.2. Subcutaneous
    • 13.6.3. Intravenous
  • 13.7. Market Attractiveness, by Route of Administration
  • 13.8. Market Value Forecast, by End-user, 2020-2034
    • 13.8.1. Hospitals
    • 13.8.2. Specialty Clinics
    • 13.8.3. Homecare Settings
    • 13.8.4. Others (Research Centers, etc.)
  • 13.9. Market Attractiveness, by End-user
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Vaccine Type
    • 13.11.2. By Method of Inactivation
    • 13.11.3. By Route of Administration
    • 13.11.4. By End-user
    • 13.11.5. By Country/Sub-region

14. Latin America Inactivated Vaccines Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 14.2.1. Viral Vaccine
    • 14.2.2. Bacterial Vaccine
  • 14.3. Market Attractiveness, by Vaccine Type
  • 14.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 14.4.1. Solvent Detergent Method
    • 14.4.2. Radiation Method
    • 14.4.3. pH Concentration
    • 14.4.4. Others (Heat Inactivation, etc.)
  • 14.5. Market Attractiveness, by Method of Inactivation
  • 14.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.6.1. Oral
    • 14.6.2. Subcutaneous
    • 14.6.3. Intravenous
  • 14.7. Market Attractiveness, by Route of Administration
  • 14.8. Market Value Forecast, by End-user, 2020-2034
    • 14.8.1. Hospitals
    • 14.8.2. Specialty Clinics
    • 14.8.3. Homecare Settings
    • 14.8.4. Others (Research Centers, etc.)
  • 14.9. Market Attractiveness, by End-user
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Vaccine Type
    • 14.11.2. By Method of Inactivation
    • 14.11.3. By Route of Administration
    • 14.11.4. By End-user
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Inactivated Vaccines Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 15.2.1. Viral Vaccine
    • 15.2.2. Bacterial Vaccine
  • 15.3. Market Attractiveness, by Vaccine Type
  • 15.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 15.4.1. Solvent Detergent Method
    • 15.4.2. Radiation Method
    • 15.4.3. pH Concentration
    • 15.4.4. Others (Heat Inactivation, etc.)
  • 15.5. Market Attractiveness, by Method of Inactivation
  • 15.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 15.6.1. Oral
    • 15.6.2. Subcutaneous
    • 15.6.3. Intravenous
  • 15.7. Market Attractiveness, by Route of Administration
  • 15.8. Market Value Forecast, by End-user, 2020-2034
    • 15.8.1. Hospitals
    • 15.8.2. Specialty Clinics
    • 15.8.3. Homecare Settings
    • 15.8.4. Others (Research Centers, etc.)
  • 15.9. Market Attractiveness, by End-user
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Vaccine Type
    • 15.11.2. By Method of Inactivation
    • 15.11.3. By Route of Administration
    • 15.11.4. By End-user
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. GSK plc
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Novartis AG
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Mylan N.V.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Sanofi S.A.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Boehringer Ingelheim International GmbH
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Merck & Co., Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. F. Hoffmann-La Roche AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Bristol-Myers Squibb Company
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Bharat Biotech
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Serum Institute of India
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. INOVIO Pharmaceuticals, Inc.
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview

List of Tables

  • Table 01: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 02: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 03: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 04: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 05: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 06: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 07: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 08: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 09: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 10: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 11: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 13: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 14: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 15: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 16: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 18: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 19: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 20: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 21: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 23: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 24: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 25: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 26: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 28: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 29: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 30: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Inactivated Vaccines Market Size (US$ Bn), by Region, 2023 and 2034
  • Figure 02: Global Inactivated Vaccines Market Revenue (US$ Bn), by Vaccine Type, 2023
  • Figure 03: Global Inactivated Vaccines Market Value Share, by Vaccine Type, 2023
  • Figure 04: Global Inactivated Vaccines Market Revenue (US$ Bn), by Method of Inactivation, 2023
  • Figure 05: Global Inactivated Vaccines Market Value Share, by Method of Inactivation, 2023
  • Figure 06: Global Inactivated Vaccines Market Revenue (US$ Bn), by Route of Administration, 2023
  • Figure 07: Global Inactivated Vaccines Market Value Share, by Route of Administration, 2023
  • Figure 08: Global Inactivated Vaccines Market Revenue (US$ Bn), by End-user, 2023
  • Figure 09: Global Inactivated Vaccines Market Value Share, by End-user, 2023
  • Figure 10: Global Inactivated Vaccines Market Value Share, by Region, 2023
  • Figure 11: Global Inactivated Vaccines Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 12: Global Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 13: Global Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 14: Global Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 15: Global Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 16: Global Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 17: Global Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 18: Global Inactivated Vaccines Market Revenue (US$ Bn), by End-user, 2023
  • Figure 19: Global Inactivated Vaccines Market Value Share, by End-user, 2023
  • Figure 20: Global Inactivated Vaccines Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Inactivated Vaccines Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Inactivated Vaccines Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Inactivated Vaccines Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 26: North America Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 27: North America Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 28: North America Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 29: North America Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 30: North America Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 31: North America Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 32: North America Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 33: Europe Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 37: Europe Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 38: Europe Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 39: Europe Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 40: Europe Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 41: Europe Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 42: Europe Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 43: Europe Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 44: Asia Pacific Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 48: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 49: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 50: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 52: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 53: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 54: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 55: Latin America Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 59: Latin America Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 60: Latin America Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 61: Latin America Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 62: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 63: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 64: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 65: Latin America Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 66: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 70: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 71: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 72: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 73: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 74: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 75: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 76: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034